Diagonal Bio AB (DIABIO) - Total Assets
Based on the latest financial reports, Diagonal Bio AB (DIABIO) holds total assets worth Skr29.10 Million SEK (≈ $3.13 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check DIABIO cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Diagonal Bio AB - Total Assets Trend (2020–2024)
This chart illustrates how Diagonal Bio AB's total assets have evolved over time, based on quarterly financial data. Check DIABIO tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Diagonal Bio AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Diagonal Bio AB's total assets of Skr29.10 Million consist of 9.6% current assets and 90.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 3.0% |
| Accounts Receivable | Skr0.00 | 0.0% |
| Inventory | Skr548.00K | 2.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr24.52 Million | 90.4% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Diagonal Bio AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Diagonal Bio AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Diagonal Bio AB's current assets represent 9.6% of total assets in 2024, a decrease from 40.1% in 2020.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2024, down from 36.8% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 90.0% of total assets, an increase from 59.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 90.4% of total assets.
Diagonal Bio AB Competitors by Total Assets
Key competitors of Diagonal Bio AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Diagonal Bio AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.05 | 1.85 | 3.70 |
| Quick Ratio | 1.31 | 1.30 | 3.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr2.23 Million | Skr2.09 Million | Skr2.92 Million |
Diagonal Bio AB - Advanced Valuation Insights
This section examines the relationship between Diagonal Bio AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.24 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -4.8% |
| Total Assets | Skr27.13 Million |
| Market Capitalization | $703.53K USD |
Valuation Analysis
Below Book Valuation: The market values Diagonal Bio AB's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Diagonal Bio AB's assets decreased by 4.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Diagonal Bio AB (2020–2024)
The table below shows the annual total assets of Diagonal Bio AB from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr27.13 Million ≈ $2.92 Million |
-4.82% |
| 2023-12-31 | Skr28.51 Million ≈ $3.07 Million |
-16.22% |
| 2022-12-31 | Skr34.03 Million ≈ $3.66 Million |
-5.50% |
| 2021-12-31 | Skr36.01 Million ≈ $3.88 Million |
+261.06% |
| 2020-12-31 | Skr9.97 Million ≈ $1.07 Million |
-- |
About Diagonal Bio AB
Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid an… Read more